Biogen: all 548 studies

Page 5 of 6. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.

• Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy VolunteersCompletedNCT01500408Phase 1
• An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)CompletedNCT01494701Phase 1
• Canadian Avonex PEN Productivity StudyCompletedNCT01489748
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
• An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical PracticeCompletedNCT01480063
• A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone MethylCompletedNCT01461161Phase 1
• Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy VolunteersCompletedNCT01453426Phase 1
• Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012CompletedNCT01420458Phase 1
• A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsCompletedNCT01416207Phase 1
• Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy VolunteersCompletedNCT01407406Phase 1
• Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.CompletedNCT01405872
• Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.CompletedNCT01405833Phase 1
• Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's DiseaseCompletedNCT01397539Phase 1
• Avonex PEN Satisfaction and Patients Experience Clinical TrialCompletedNCT01366040
• A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy SubjectsCompletedNCT01365338Phase 1
• Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 DiabetesTerminatedNCT01351675Phase 3
• A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch NeedleTerminatedNCT01313364Phase 1
• Alternate Dosing Regimens of BG00012 in Healthy VolunteersCompletedNCT01281111Phase 1
• Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL StudyCompletedNCT01272128
• Safety Study of BIIB033 in Subjects With Multiple SclerosisCompletedNCT01244139Phase 1
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult VolunteersTerminatedNCT01238679Phase 1
• Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.CompletedNCT01235221Phase 3
• A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy VolunteersCompletedNCT01215084Phase 1
• Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive PatientsCompletedNCT01211678
• Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal LeukoencephalopathyTerminatedNCT01211639
• JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)CompletedNCT01185717
• Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)CompletedNCT01181115Phase 3
• Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT01181089Phase 1/2
• First-in-Human Study of PF-04958242 in Healthy VolunteersCompletedNCT01159483Phase 1
• Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological SurveillanceTerminatedNCT01156298
• Safety Study of RP-1127 (Glyburide for Injection) in Healthy VolunteersCompletedNCT01132703Phase 1
• A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy VolunteersCompletedNCT01119781Phase 1
• A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy VolunteersCompletedNCT01119677Phase 1
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabCompletedNCT01070836
• JC-Virus (JCV) Antibody ProgramCompletedNCT01070823
• Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical IngredientCompletedNCT01069913Phase 1
• A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple SclerosisCompletedNCT01065090
• Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT01053936Phase 2
• BIIB033 Single Ascending Dose Study in Healthy Volunteer SubjectsCompletedNCT01052506Phase 1
• BIIB014 Cardiovascular Monitoring StudyCompletedNCT01035515Phase 1
• BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and MidazolamCompletedNCT01017666Phase 1
• Effect of Food and Antacid on BIIB021 With Advanced Solid TumorsCompletedNCT01017198Phase 1
• Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule FindingCompletedNCT01004081Phase 2
• A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung CancerCompletedNCT00970580Phase 1
• Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy SubjectsTerminatedNCT00964288Phase 1
• Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica ParticipantsCompletedNCT00961766Phase 1
• Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)CompletedNCT00956436Phase 1
• Study to Investigate the Effect of GSK1014802 on Ambulatory Blood PressureCompletedNCT00955396Phase 1
• Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex SyringeCompletedNCT00915577Phase 3
• Open-Label Safety Extension Study of AvonexCompletedNCT00915460Phase 4
• Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy VolunteersCompletedNCT00913666Phase 4
• A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy VolunteersCompletedNCT00913250Phase 1
• Immunogenicity and Safety Study of Serum-Free AvonexCompletedNCT00912860Phase 2
• Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.CompletedNCT00908154Phase 1
• Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSCompletedNCT00884481
• Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)WithdrawnNCT00878761Phase 2
• BG9928 in Subjects With Hepatic ImpairmentCompletedNCT00858156Phase 1
• A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSCompletedNCT00837785Phase 1
• A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201TerminatedNCT00831649Phase 2
• A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder FunctionCompletedNCT00818038
• Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT00811889Phase 2
• Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedNCT00810836Phase 2
• Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α TherapyWithdrawnNCT00801125Phase 4
• Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00801060Phase 2
• BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid ArthritisCompletedNCT00771329Phase 1
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
• Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal InsufficiencyTerminatedNCT00745316Phase 2
• A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady StateCompletedNCT00744679Phase 4
• Administration of BIIB028 to Subjects With Solid TumorsCompletedNCT00725933Phase 1
• Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal InsufficiencyCompletedNCT00709865Phase 3
• CD INFORM: Investigating Natalizumab Through Further Observational Research and MonitoringTerminatedNCT00707512
• COMPliance With Avonex® PS in Patients With Relapsing-Remitting MSCompletedNCT00675883
• A Phase I Study of BIIB015 in Relapsed/Refractory Solid TumorsCompletedNCT00674947Phase 1
• Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) ParticipantsCompletedNCT00664716Phase 2
• 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) ParticipantsTerminatedNCT00664573Phase 2
• Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic NephropathyCompletedNCT00664027Phase 2
• Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's LymphomaTerminatedNCT00651443Phase 1
• Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid TumorsCompletedNCT00618735Phase 1
• An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00618319Phase 2
• ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.CompletedNCT00618267
• Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple SclerosisCompletedNCT00599274
• Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00575068Phase 1/2
• How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
• Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid TumorsCompletedNCT00555724Phase 1
• Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic DysfunctionTerminatedNCT00550849Phase 1/2
• RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain MetastasesTerminatedNCT00538343Phase 2
• Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant MelanomaWithdrawnNCT00535314Phase 2
• Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
• Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male VolunteersCompletedNCT00531193Phase 1
• RTA 402 in Patients With Advanced Solid Tumors or Lymphoid MalignanciesCompletedNCT00529438Phase 1
• Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic CancerTerminatedNCT00529113Phase 1
• A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic MeningitisTerminatedNCT00527410Phase 1
• A Safety Study of RTA 744 in Patients With Recurrent High-Grade GliomasCompletedNCT00526812Phase 1
• Avonex 15 Year Long Term Follow-up StudyCompletedNCT00525343
• BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)TerminatedNCT00523328Phase 2
• Tysabri Observational ProgramCompletedNCT00493298
• Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
• Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta TherapyCompletedNCT00493077Phase 4
• Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT00492765Phase 4

← Biogen overview and focus areas